Impact of Drug Coverage on Medical Expenditures
and chronic condition (hypertension, heart disease, and arthritis) . We find that drug coverage has no discernible effect on the use and cost of inpatient services, but is associated with a statistically significant increase in Medicare spending for physician services. The benefit remains controversial in large part because it is expected to be hugely expensive, adding more than $900 billion to Medicare spending over the next 10 years and representing an increase in total Medi care benefit outlays of 15 percent (U.S. Congressional Budget Office, 2007) .
The net longterm increase in Medicare spending for outpatient drugs may prove to be lower than this if both of two things occur: (1) Part D significantly increases access to appropriate medications and (2) the use of Medicare covered medical ser vices is sensitive to the use of prescription medications. For example, if the introduc tion of Part D results in an increase in the use of statin drugs by beneficiaries at ele vated risk for myocardial infarction or stroke, and if the probability of myocardial infarction or stroke is substantially reduced by the use of statins, then Part D spend ing on statins might be offset by reduced spending for emergency department and inpatient care. However, the drug ben efit may increase the cost of medical care if drug and nondrug medical services, such as physician office visits for prescrib ing and monitoring medications, are com plementary or if pharmaceuticals lead to adverse events or medical complications.
Evidence that enhanced access to pre scription drugs reduces health care utili zation is mixed. Yang and Norton (2006) use Medicare Current Beneficiary Sur vey (MCBS) data to show that an increase in outpatient prescription drug use (not coverage) leads to minor, but significant offsets in Medicare inpatient spending. Furukawa (2004) , employing the same source of data, finds that Medicare bene ficiaries with private drug coverage have significantly lower nondrug spending than those without drug coverage, although the offset varies by source of coverage and type of service. Khan, Kaestner, and Lin (2007) also use MCBS data to analyze the impact of drug coverage on service use and find that prescription drug cover age significantly increases the utilization of prescription medications, but has no discernable effect on hospital admissions.
Our study contributes to this literature by exploiting a natural experiment created by the implementation of State pharmacy assistance programs for lowincome ben eficiaries. We evaluate the impact of drug coverage on medical costs by comparing expenditures for Medicare covered medi cal services among enrollees in three State pharmacy assistance programs in 2003 with medical spending for lowincome res idents who were eligible or near eligible for, but not enrolled in Statesponsored programs over the same period. Using information collected through enrollee and nonenrollee surveys, we control for differ ences in demographic, socioeconomic, and health status characteristics between the two groups. Utilization and expenditure effects are estimated in total and for inpa tient, hospital outpatient, and physician services separately.
POliCY COnteXt
In 2003, Vermont offered three phar macy benefit programs to its lowincome elderly and disabled residents (Table 1) 
eligibility requirements
Eligibility for VHAP Pharmacy, VScript, and VScript Expanded was based on a range of criteria including: age, disabil ity, income, residency, and private phar macy coverage. Enrollees were required to be age 65 or over receiving disability benefits from Social Security Old Age Sur vivors and Disability Insurance (OASDI), Medicare, or Railroad Retirement. Individ uals were not allowed to be receiving assis tance for prescription drug expenses at the time of enrollment. 1 However, those with a privately purchased supplemental phar maceutical benefit could drop coverage without penalty or downgrade to a physi cian and hospital benefit only to qualify for State drug assistance. At the time of appli cation, individuals were required to be U.S. citizens or resident aliens lawfully admitted for permanent residence and living in Ver mont. Individuals who met these require ments, but who did not otherwise qualify for Medicare benefits because of the dis ability waiting period, citizenship, or lack of prior employment nonetheless remained eligible for the State drug assistance pro grams. The three programs also had income (but not asset) requirements, which were expanded over time. At the time of our study, the income threshold was 150 percent of the Federal poverty level (FPL) for VHAP Pharmacy, 175 percent of FPL for VScript, and 225 percent of FPL for the Statefunded VScript Expanded program.
Pharmacy Benefits
Given their traditional reliance on State only funds, the priority of VScript and VScript Expanded was on prescription drugs considered essential for maintaining the health of seniors and disabled people suffering from chronic conditions, such as hypertension, asthma, and diabetes. Indi viduals who depend on prescription drugs to control their chronic conditions were considered most vulnerable to the lack of a Medicare drug benefit and, thus, most in need of public pharmacy assistance from the State. Thus, under VScript and VScript Expanded, only maintenance drugs were covered. Maintenance drugs were defined as all medications for which a single 60day supply is prescribed, excluding those pri marily used for the treatment of acute con ditions. With the introduction of the 1115 waiver and access to Federal funds, VHAP Pharmacy covered all prescription drugs, including contraception medications and devices, insulin supplies, and needles and syringes. In April 1999, when VScript for individuals between 150 and 175 percent of FPL became absorbed into the waiver, coverage remained restricted to mainte nance prescription drugs. Enrollees in all three programs were required to use a generic drug whenever available, unless a brand named drug was recommended by the prescribing physician.
Despite differences in benefits between the VHAP program and the VScript and VScript Expanded programs, an earlier analysis of drug claims data revealed that enrollees in VHAP Pharmacy and VScript were equally likely to suffer from chronic illnesses and use similar types and amounts of prescription drugs (Gilman, Gage, and Mitchell, 2003) . Our review of pharmacy claims found that the types of drugs most commonly purchased under both VHAP Pharmacy and VScript were used to treat the same set of chronic con ditions, including stomach acids or ulcers, cholesterol, heart disease, diabetes, and mental disorders. In fact, the eight top ranking prescription medications in terms of both number of users and expenditures were the same for both programs. The authors found broad similarities in self reported chronic disease prevalence and health status indicators across the three pharmacy assistance programs as well (Gilman et al., 2004a) .
enrollee Cost Sharing
VHAP Pharmacy, VScript, and VScript Expanded required enrollee cost shar ing, which also underwent major changes since each program's inception. By 2003, the VHAP Pharmacy and VScript pro grams were using a twotiered copayment system with a quarterly outofpocket max imum. For generic drugs, VHAP Phar macy participants paid a $3 copayment and VScript enrollees paid a $5 copayment. For brand named drugs, VHAP Pharmacy and VScript participants paid a $6 and $10 copayment, respectively. Enrollee copay ments were limited to $50 per quarter under VHAP Pharmacy and $100 per quar ter under VScript. In contrast, the fully Statefunded VScript Expanded program used a 41.25percent coinsurance rate and a $275 annual deductible. Beneficiary out ofpocket payments were limited to $2,500 per year under VScript Expanded.
Data anD MetHODS

Data Sources
We collected information on beneficia ries' demographic, socioeconomic, and health status characteristics from surveys of enrolleed and eligible or neareligible nonenrolleed beneficiaries (Gilman, et al., 2004b) . 2 Data were collected by telephone during a 12week period between March and June 2004. A total of 2,680 18minute interviews were completed. Of these inter views, 1,356 were completed with benefi ciaries in the enrollee group and 1,324 were completed with beneficiaries in the eligible or near eligible but nonenrollee group. The unweighted response rate was 77 percent for the enrollee group and 72 percent for nonenrollee. The sampling weights were adjusted for survey non response and poststratified to popu lation control totals. The surveys collected in formation on drug coverage prior to enrollment, drug utilization, access to pre scription drugs, adequacy of drug cover age, and unmet drug needs. The surveys also collected information on selfreported health status, nine chronic diseases, socio demographic characteristics (education, employment, income, and living arrange ment), supplemental medical coverage, and drug coverage (among nonenrollees).
We obtained information on medical service use and expenditures from the 2003 Medicare claims files, including the inpatient, outpatient, and physician/sup plier Standard Analytic Files. Details on program enrollment came from the State Medicaid eligibility files. State eligibility files provide a complete record of dates of enrollment by type of program, includ ing VHAP Pharmacy, VScript, and VScript Expanded. State eligibility files were also used to identify the program enrollee survey frame. We used the Medicare Enrollment Database (EDB) to collect information on additional beneficiary char acteristics such as sex, age, and dual Med icaid eligibility status, and to identify the nonenrollee survey frame.
Study Sample
We drew the enrollee sample from a frame of all Medicare beneficiaries who were enrolled in any of the State pharmacy assistance programs on November 1, 2003. We divided the enrollee sample into three balanced strata, one for each of the phar macy assistance programs, to allow within group comparisons based on the coverage benefits and copayment requirements. We drew the nonenrollee sample from a frame of elderly Medicare beneficiaries who were a resident of Vermont in November 2003, were not enrolled in any of the State phar macy assistance programs, and had an annual income below 300 percent of FPL. We used a screener to identify lowincome nonenrollees based on selfreported in come. We also used Social Security income data provided by the Social Security Admin istration to identify beneficiaries who, on the basis of their monthly benefits, were likely to have annual incomes close to the eligibility thresholds for the pharmacy assistance programs and help narrow our nonenrollee frame. We excluded nonel derly beneficiaries from both the enrollee and nonenrollee samples.
Model
We used a crosssectional evaluation design in which the impact of drug cov erage is measured as the difference in average medical expenditures among a representative sample of enrollees in VHAP Pharmacy, VScript, and VScript Expanded and a representative sample of Medicare beneficiaries who were eligi ble or near eligible for but not enrolled in any of the Statesponsored assistance pro grams, after controlling for differences in health status and other potentially con founding factors such as supplemental medical coverage between the two groups.
The expenditure model can be summa rized as follows:
where Y i = annualized total expenditures for beneficiary i; α = the intercept term; X i = a set of beneficiarylevel sociode mographic characteristics; H i = a set of beneficiarylevel health sta tus characteristics; P i = a set of beneficiarylevel health coverage characteristics; E i = an enrollment dummy that takes the value of one for all program enrollees and zero otherwise; and ε = a random error term.
The model regresses total expenditures from all sources, including Medicare, third party payers, and beneficiary copayments, on a set of beneficiarylevel sociodemo graphics, health status, and plan coverage characteristics, plus an enrollment vari able that takes the value of one for all ben eficiaries enrolled in any of the three State pharmacy assistance programs and zero for all eligible or near eligible, but nonen rolled beneficiaries without drug coverage. A positive sign on the estimated enrollment coefficient signifies that drug coverage and service use are complements; a negative coefficient indicates prescription drugs are a substitute for medical services.
Medicare beneficiaries are likely to en roll in subsidized programs precisely because they experience an acute episode or suffer from chronic illnesses with exten sive and persistent health care needs (Gil man, Gage, and Mitchell, 2003; Pauly and Zeng, 2003) . Beneficiaries with greater health care needs are thus more likely to enroll in pharmacy assistance programs than beneficiaries with lower levels of need. To control for the potential bias caused by adverse selection, we include several health status measures, as well as a set of demographic and socioeconomic characteristics that are likely to be corre lated with health status. The covariates include age (6574 years, 7584 years, and 85 years or over); sex; residency status (whether or not an individual lived alone); education (less than high school, high school only, and some posthigh school); and income (less than 151 percent of FPL and between 151300 percent of FPL). We also include selfreported health sta tus (excellent/very good, good, and fair/ poor), and a set of selfreported chronic conditions (hypertension or high blood pressure; heart disease or condition; emphysema, asthma or chronic obstruc tive pulmonary disease (COPD); cancer or other malignancy; diabetes or high blood sugar; arthritis; osteoporosis or fragile or soft bones; depression; and stomach ulcer, heartburn or reflux).
The model may also produce biased results if the enrollee and nonenrollee samples have differential rates of supple mental medical insurance or if the nonen rollee sample has drug coverage or a drug discount card. (All program enrollees are eligible for the Healthy Vermonters drug discount card program that entitles them to Medicaid prices on prescription drugs.) To control for the effect of supplemen tal medical and nonState drug coverage, we include a variable that takes the value of one if a beneficiary has supplemental medical insurance coverage and zero oth erwise and another variable that takes the value of one if a nonenrollee reports hav ing drug coverage and zero otherwise. We also include an indicator variable for non enrollees who report owning a drug dis count card. These variables effectively create a second treatment arm of nonen rollees with drug coverage. Our program enrollment variable thus measures the dif ference in service use and expenditures between program enrollees and nonen rolled beneficiaries who do not have an alternative source of drug coverage or a drug discount card.
Statistical Methods
The model is estimated on logged Medi care payments to account for the skewness of drug expenditures. Because of the non trivial proportion of beneficiaries without a claim, the results were estimated using a twopart model. The twopart model esti mates the probability of any expenditure and the level of nonzero expenditures among claimants separately. The prob ability model is estimated using logis tic regression and the conditional logged expenditure model is estimated using ordi nary least squares. We use group and servicespecific smearing factors based on individual residuals to retransform the results to the original dollar scale and employ bootstrapping methods to estimate the standard errors from the twopart model. To control for differences in length of Medicare enrollment, we weight the observations by the proportion of the year a person is alive and entitled to both Parts A and B benefits. Since most enrollees are enrolled for 12 months, we did not adjust for partial year enrollment. Nor did we adjust for length of enrollment in the phar macy assistance programs historically.
We estimate the model on total expendi tures for inpatient, hospital outpatient, and physician services separately to measure differences in the relationship between drug and nondrug care across individual service categories. Inpatient expenditures include facility payments for services pro vided in an acute care hospital, skilled nursing facility, or longterm care hospital setting. Outpatient expenditures include facility payments for services administered in a hospital outpatient department or a freestanding ambulatory care clinic. Phy sician expenditures consist of payments for professional services provided in any setting, including a physician's office. We hypothesize that drugs are more likely to substitute for acute care services administered in inpatient facilities, while pharmaceuticals are more likely to be com plementary with services oriented toward disease prevention and maintenance that are administered in physicians' offices or outpatient clinics.
We reestimate the models using pro gramspecific enrollment variables to exam ine the differential effect of benefit design on medical service use and costs. Plans with more generous formularies and cost sharing requirements might encourage greater use of and adherence to prescrip tion medications and, thus, lead to greater substitution with inpatient services and complementarities with ambulatory ser vices. Since VHAP Pharmacy covered more drugs and charged a lower copayment, we would expect to see a larger coverage effect under the more generous program.
Alternatively, the substitution of drug for nondrug medical services administered in an inpatient setting may be greater among beneficiaries with chronic diseases who rely on maintenance medications to con trol their conditions. Complementarities between drug and physician or outpatient services may be greater among those with chronic conditions as well. In this case, we would expect the impact of drug cover age on medical service use and spending to be greater among VScript and VScript Expanded enrollees. To test this hypoth esis, we reestimated the models sepa rately on the three most prevalent chronic conditions in our sample: hypertension, arthritis, and heart disease or condition. Table 2 shows the distribution of en rollee and nonenrollee samples by demo graphic, socioeconomic, health status, and insurance coverage attributes. The enrollee and nonenrollee samples consist of 1,310 and 1,295 elderly beneficiaries, respectively. Enrollees were more likely to be very old, female, and living alone. They were also less likely to have graduated from high school or have some post high school edu cation. In addition, enrollees had lower selfreported health status (fair/poor) and were more likely to suffer from chronic conditions such as hypertension, heart and lung disease, diabetes, arthritis, osteo porosis, mental depression, and stomach ulcers. Enrollees were also more likely to use prescription medications and, among those who did, to fill more prescriptions per year. Enrollees were also less likely to have supplemental medical coverage. Over twothirds of the nonenrollee sample had drug coverage and almost onethird had a drug discount card. Differences between the enrollee and nonenrollee samples are statistically significant. Table 2 provides similar statistics for annual drug use and spending by service category. Enrollees were more likely to use outpatient and professional services, but no more likely to have a hospitaliza tion than nonenrollees. The betweengroup differences in outpatient and professional Table 3 presents the estimated coeffi cients and standard errors from the logis tic and conditional expenditure models separately. The results reveal that the odds of using inpatient services are positively correlated with age, and the odds of using outpatient services are positively associ ated with being female. The odds of using physician services are also significant and positively correlated with age, female, and income. Medical expenditures for physi cian services conditional on using those services were significant and positively correlated with age and education.
reSUltS
Descriptive Statistics
The findings also indicate that self reported health status is positively cor related with the odds of using inpatient services and conditional expenditures for outpatient and professional services. A similar pattern of higher use rates and conditional expenditures holds true for most individual disease conditions as well, although the significance of the results varies depending on the number of bene ficiaries who reported having the disease. Beneficiaries with heart and lung disease were more likely to use inpatient services, and those who suffered from arthritis, osteoporosis, and stomach ailments were more likely to use outpatient services.
Most of these conditions, together with hypertension and cancer, were also asso ciated with a greater likelihood of visiting a physician or other professional service provider. Moreover, while having a medi cal condition has no discernible effect on inpatient expenditures, the impact on out patient and professional expenditures is generally positive and significant.
Beneficiaries who had supplemental medi cal insurance were over 60 percent more likely to use outpatient services and over twice as likely to use professional ser vices as those who did not have additional medical coverage. Elderly beneficiaries with a privately purchased or retiree drug benefit (those who were not enrolled in one of the State's subsidized drug programs) exhibited higher conditional expendi tures for outpatient services than individu als without drug coverage. Ownership of a drug discount card had no observable effect on use or cost of Medicare services. Finally, the firstpart results indicate that enrollment in a Statesponsored pharmacy assistance program has no observable impact on individual service use and costs. However, when aggregated over all service categories, subsidized drug coverage was associated with a marginally significant doubling of the odds of using Medicare covered services. with higher expenditures for outpatient and professional services. The twopart results also provide evi dence that both supplemental medical and drug coverage (including both privately purchased and subsidized drug plans) are positively associated with higher Medicare spending for ambulatory services, after controlling for crosssectional differences in health status. Elderly beneficiaries with supplemental medical coverage exhibited $194 (18 percent) higher costs for outpa tient services and $229 (15 percent) higher costs for professional services than those without supplemental medical insurance. Similarly, beneficiaries with a privately purchased or retiree drug plan incurred $286 (26 percent) more in outpatient costs and $219 (14 percent) in professional costs than those without any drug coverage. Beneficiaries with a drug discount card exhibited higher spending for outpatient and professional services as well. Finally, enrollment in one of the Statesponsored pharmacy assistance programs was asso ciated with a $263 (17 percent) increase in expenditures for professional services relative to beneficiaries without any drug coverage. Enrollment in a subsidized drug plan had no statistically significant effect on Medicare expenditures for hospital inpatient or outpatient services. Table 5 presents the twopart results by type of pharmacy assistance program. Only the estimated coefficients and stan dard errors for the program enrollment variables are shown. Medicare spending for professional services was $486 higher among VScript enrollees and $527 higher among VScript Expanded enrollees rela tive to beneficiaries without any drug cov erage. VScript Expanded enrollees also exhibited marginally significant higher costs ($264) for outpatient services. As a result of higher ambulatory costs, total spending over all service categories was $1,132 higher among VScript enrollees and $1,485 higher among VScript Expanded enrollees relative to those without drug coverage. None of the results for the VHAP Pharmacy program (across all ser vice categories) and for inpatient services (across all pharmacy assistance programs) is statistically significant.
two-Part expenditure results
We also reestimated the twopart model separately for beneficiaries who reported having hypertension, arthritis, and heart disease. The conditionspecific results, presented in Table 5 , reveal a marginally significant negative correlation between subsidized drug coverage and inpatient expenditures for beneficiaries with hyper tension ($907) and a positive correla tion between subsidized drug coverage and professional expenditures for those with hypertension ($207) and heart dis ease ($432), relative to noncovered ben eficiaries with these diseases. Pharmacy assistance program enrollees with heart disease also exhibited marginally signifi cant higher Medicare expenditures over all service categories ($1,266).
DiSCUSSiOn
The results of this study suggest that outpatient prescription drugs may serve as a complement for professional ser vices among the elderly. Enrollment in Vermont's pharmacy assistance programs was associated with a statistically signifi cant 17 percent increase in annual expen ditures for professional services compared with lowincome beneficiaries without drug coverage after controlling for differ ences in health status. Similarly, beneficia ries covered under a privately purchased or retiree drug plan had 26 percent higher outpatient costs and 14 percent higher physician costs relative to individuals with out drug coverage. The results suggest that greater access to outpatient prescription drugs lead to more time with physicians for prescrib ing medications, and may require more regular monitoring of treatment regimes and potential side effects by a physician or other professional provider. While some studies using MCBS data have sug gested that prescription drugs may be a substitute for inpatient services, the nega tive offsets associated with inpatient ser vices observable in our study were not statistically significant.
The complementarity effects appear strong est among beneficiaries who suf fer from chronic conditions. Enrollees in VScript and VScript Expanded expe rienced the largest and most significant increase in Medicare payments for ambu latory services. Annual payments for pro fessional services increased 26 percent for VScript enrollees and 18 percent VScript Expanded participants, relative to ben eficiaries without drug coverage. In fact, participants in the maintenance medica tiononly programs experienced a large and statistically significant relative increase in total medical payments, suggesting that the complementarities between drugs and physician services may outweigh the potential substitution between drugs and inpatient services among beneficia ries with chronic conditions. The comple mentarity between outpatient prescription drugs and professional services was fur ther evidenced when estimated over ben eficiaries with specific chronic conditions. Expenditures for professional services increased 19 percent for enrollees with hypertension and 24 percent for those with heart disease relative to beneficiaries with the same condition without drug coverage.
Evidence from Vermont's pharmacy assistance programs suggests that en hanced access to outpatient prescrip tion drugs under Part D may not lead to discernible offsets in spending on other Medicare covered medical services, at least when measured across all lowincome beneficiaries. While the findings from this natural experiment show a relative reduc tion in the use and cost of inpatient ser vices among enrollees in Statesponsored programs, the results are not statistically significant. In fact, our study suggests that improvements in drug coverage under (Cauchi et al., 2007; Fox and Schofield, 2006) .
Contributions toward wraparound ser vices for waivered enrollees no longer qualify for Federal matching funds, but count toward enrollee's true outofpocket spending costs, which helps individuals reach the catastrophic coverage thresh old. The results of our study suggest that, while these wrap around programs may improve access to drugs among the near poor, they are unlikely to lower Medi care spending and may in fact increase expenditures for physician services. 
